Floatz logo

SEVIPROTIMUT-L

Breast Cancer

Applied Biology, Inc.vaccineEarly Phase 1Dormant
D
31/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
22/ 100
Competitive Position
59/ 100

Competitive context

686 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
IMMUNOGLOBULIN G1, ANTI-(HUMAN NEU (RECEPTOR)) (HUMAN-MOUSE MONOCLONAL 2C4 HEAVY CHAIN), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL 2C4 .KAPPA.-CHAIN, DIMER
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
VITAMIN D
University of Illinois at Chicago
Phase 4BB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

SEVIPROTIMUT-L is also rated in:

Relapsed or Refractory Hodgkin LymphomaDormant
CC
Indicative ·
43 / 100
View asset →
melanomaDormant
CC
Indicative ·
43 / 100
View asset →
Peripheral T Cell LymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →